



FOR IMMEDIATE RELEASE: February 7, 2025

CONTACT: Krysia Lenzo, klenzo@empirestrategy.com

LAMASSU BIOTECH SET TO ATTEND LEAP 2025

International Conference in Saudi Arabia An Opportunity to Highlight Synergy Between Technology and Medicine

(CLEVELAND, OH) — Lamassu Biotech, a pioneering biotechnology company dedicated to developing breakthrough treatments for challenging diseases, will attend LEAP 2025, the premier global technology conference in Riyadh, Saudi Arabia. Known as a “digital Davos,” LEAP provides a unique opportunity for Lamassu Biotech’s leadership to engage with international experts driving the convergence of technology, AI, data science, and healthcare—an intersection that is rapidly transforming early cancer detection, pharmaceutical advancements, and patient care.

Gabi Hanna, M.D., CEO and co-founder of Lamassu Biotech, emphasized the company’s commitment to leveraging cutting-edge technology to improve cancer detection and develop next-generation therapies.

“We believe strongly in the value of technology to improve the health care industry, and outcomes for patients facing serious diagnoses like chemo-resistant cancers. Our SA53 MDM2 therapy is a genetically targeted treatment that has demonstrated remarkable potency, efficacy and safety in preclinical models. LEAP provides us with an opportunity to engage with others leaders who might be developing cohesive technology that could help accelerate hope and healing.”

As a biotechnology company operating at the intersection of technology and pharmaceuticals, Lamassu Biotech is dedicated to utilizing advancements in AI, machine learning, and computational biology to improve therapeutic development, enhance precision medicine, and optimize drug delivery systems. By integrating the latest breakthroughs in data science with traditional pharmaceutical methodologies, Lamassu is driving innovation in the biotech space—delivering better therapies, improving quality of life, and extending longevity for patients facing serious diseases.

“LEAP has a proven track record of bringing together hundreds of thousands of leaders from around the world. With our SA53 MDM2 therapy preparing to begin human trials, it is a perfect time to connect with global industry experts and government leaders to explore new opportunities for innovation in the life sciences sector,” Hanna said. “Leaders in the Kingdom are advancing a bold vision for the future of health care and it is our hope to build partnerships that can aid in meeting that goal.”

Lamassu Biotech is pioneering biopharmaceutical research with a strong focus on developing innovative therapeutics for metastatic cancers and other unmet needs. Through strategic partnerships with leading global research institutions and industry collaborators, Lamassu Biotech is transforming the landscape of oncology and bringing potentially life-changing therapies to patients in need.

As Lamassu continues to advance its research and expand partnerships in the global biotech landscape, its focus remains on improving patient outcomes and bringing transformational treatments from concept to bedside faster than other companies.

For media inquiries or to schedule a meeting with Lamassu Biotech during LEAP 2025, please contact Krysia Lenzo at klenzo@empirestrategy.com.

###

About Lamassu Biotech

Lamassu Biotech is a pioneering pharmaceutical company focused on developing innovative treatments for severe and unmet medical needs. With decades of experience, Lamassu specializes in advancing transformational treatments from concept to bedside with efficiency and precision. At Lamassu, we believe in the transformative power of science and the hope it brings to patients and families. Learn more at LamassuBiotech.com.